Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial
Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study, boosting the Swiss drugmaker’s bid to bring a next-generation treatment to market.
By Fabienne Kinzelmann · Bloomberg
Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study, boosting the Swiss drugmaker’s bid to bring a next-generation treatment to market.